Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Increased peripheral inflammatory responses in myelin oligodendrocyte glycoprotein associated disease and aquaporin-4 antibody positive neuromyelitis optica spectrum disorder.
Bauer A, Rudzki D, Berek K, Dinoto A, Lechner C, Wendel EM, Hegen H, Deisenhammer F, Berger T, Höftberger R, Rostasy K, Mariotto S, Reindl M. Bauer A, et al. Among authors: rudzki d. Front Immunol. 2022 Nov 14;13:1037812. doi: 10.3389/fimmu.2022.1037812. eCollection 2022. Front Immunol. 2022. PMID: 36451827 Free PMC article.
Natalizumab treatment reduces endothelial activity in MS patients.
Millonig A, Hegen H, Di Pauli F, Ehling R, Gneiss C, Hoelzl M, Künz B, Lutterotti A, Rudzki D, Berger T, Reindl M, Deisenhammer F. Millonig A, et al. Among authors: rudzki d. J Neuroimmunol. 2010 Oct 8;227(1-2):190-4. doi: 10.1016/j.jneuroim.2010.07.012. Epub 2010 Aug 23. J Neuroimmunol. 2010. PMID: 20739072
Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development.
Hegen H, Millonig A, Bertolotto A, Comabella M, Giovanonni G, Guger M, Hoelzl M, Khalil M, Killestein J, Lindberg R, Malucchi S, Mehling M, Montalban X, Polman CH, Rudzki D, Schautzer F, Sellebjerg F, Sørensen PS, Deisenhammer F. Hegen H, et al. Among authors: rudzki d. Mult Scler. 2014 Apr;20(5):577-87. doi: 10.1177/1352458513503597. Epub 2013 Sep 5. Mult Scler. 2014. PMID: 24009164
Cytokine profiles show heterogeneity of interferon-β response in multiple sclerosis patients.
Hegen H, Adrianto I, Lessard CJ, Millonig A, Bertolotto A, Comabella M, Giovannoni G, Guger M, Hoelzl M, Khalil M, Fazekas F, Killestein J, Lindberg RL, Malucchi S, Mehling M, Montalban X, Rudzki D, Schautzer F, Sellebjerg F, Sorensen PS, Deisenhammer F, Steinman L, Axtell RC. Hegen H, et al. Among authors: rudzki d. Neurol Neuroimmunol Neuroinflamm. 2016 Jan 27;3(2):e202. doi: 10.1212/NXI.0000000000000202. eCollection 2016 Apr. Neurol Neuroimmunol Neuroinflamm. 2016. PMID: 26894205 Free PMC article.
6-month SARS-CoV-2 antibody persistency in a Tyrolian COVID-19 cohort.
Deisenhammer F, Borena W, Bauer A, Kimpel J, Rudzki D, Schanda K, Egeter J, Hüfner K, Sperner-Unterweger B, Reindl M. Deisenhammer F, et al. Among authors: rudzki d. Wien Klin Wochenschr. 2021 Apr;133(7-8):351-358. doi: 10.1007/s00508-020-01795-7. Epub 2020 Dec 9. Wien Klin Wochenschr. 2021. PMID: 33315138 Free PMC article.
12-month SARS-CoV-2 antibody persistency in a Tyrolean COVID-19 cohort.
Deisenhammer F, Bauer A, Kavelar C, Rudzki D, Rössler A, Kimpel J, Borena W, Reindl M. Deisenhammer F, et al. Among authors: rudzki d. Wien Klin Wochenschr. 2021 Dec;133(23-24):1265-1271. doi: 10.1007/s00508-021-01985-x. Epub 2021 Nov 23. Wien Klin Wochenschr. 2021. PMID: 34812944 Free PMC article.
Soluble Vascular Cell Adhesion Molecule-1 (sVCAM-1) and Natalizumab Serum Concentration as Potential Biomarkers for Pharmacodynamics and Treatment Response of Patients with Multiple Sclerosis Receiving Natalizumab.
Auer M, Bauer A, Oftring A, Rudzki D, Hegen H, Bsteh G, Di Pauli F, Berek K, Zinganell A, Berger T, Reindl M, Deisenhammer F. Auer M, et al. Among authors: rudzki d. CNS Drugs. 2022 Oct;36(10):1121-1131. doi: 10.1007/s40263-022-00953-x. Epub 2022 Sep 29. CNS Drugs. 2022. PMID: 36173556
21 results